Bristol Myers bags FDA nod for blockbuster-to-be cardio drug Camzyosnews2022-04-28T11:27:35+00:00April 28th, 2022|Fierce Pharma|
Novartis rolls first Leqvio TV ads, focusing on resilient patients—and convenient dosingnews2022-04-28T07:20:04+00:00April 28th, 2022|Fierce Pharma|
Amgen vows to fight $7.1B tax bill tied to Puerto Rico manufacturing unitnews2022-04-27T21:13:19+00:00April 27th, 2022|Fierce Pharma|
‘These lives matter’: Oxfam and partners urge J&J, Pfizer and Moderna investors to focus on vaccine equity effortsnews2022-04-27T19:37:42+00:00April 27th, 2022|Fierce Pharma|
Pfizer and Biohaven clinch migraine approval in Europe, beating AbbVie to key marketnews2022-04-27T16:25:22+00:00April 27th, 2022|Fierce Pharma|
Merck’s C-suite shakeup logs another loss as marketing exec Garay leaves for Modernanews2022-04-27T15:37:12+00:00April 27th, 2022|Fierce Pharma|
Johnson & Johnson follows Gilead with lawsuit targeting alleged HIV drug counterfeitersnews2022-04-27T15:03:02+00:00April 27th, 2022|Fierce Pharma|
GlaxoSmithKline’s sales soar thanks to Shingrix, COVID-19 antibody but oncology lagsnews2022-04-27T14:11:00+00:00April 27th, 2022|Fierce Pharma|
Novartis spotlights BeiGene-partnered cancer immunotherapy data to move it earlier in the treatment paradigmnews2022-04-27T13:06:51+00:00April 27th, 2022|Fierce Pharma|
AstraZeneca staves off last Tagrisso copycat with settlement—for nownews2022-04-27T03:57:09+00:00April 27th, 2022|Fierce Pharma|
